All AbMole products are for research use only, cannot be used for human consumption.
Brivanib (BMS-540215) is an ATP-competitive inhibitor of human VEGFR -2, with an IC50 of 25 nmol/L and Ki of 26 nmol/L. Brivanib is currently in development for the treatment of hepatocellular and colon carcinomas. In vitro and in vivo studies were conducted to characterize the preclinical pharmacokinetics and disposition of brivanib and brivanib alaninate, and antitumor efficacy in mice bearing human xenografts.
 |
Source | AJR Am J Roentgenol (2014). Figure 3. Brivanib |
| Method | DCE-MRI | |
| Cell Lines | HepG2 cells | |
| Concentrations | 0.01 mL/g | |
| Incubation Time | 14 d | |
| Results | In the brivanib-treated group, the Ktrans and ve values decreased statistically significantly between baseline and 7 days after treatment (p = 0.024 and p = 0.031, respectively), and between baseline and 14 days after treatment (p = 0.043 and p = 0.018), and did not show statistically significant changes between 7 days and 14 days (p = 0.302 and p = 1, respectively). |
 |
Source | AJR Am J Roentgenol (2014). Figure 2. Brivanib |
| Method | DCE-MRI | |
| Cell Lines | HepG2 cells | |
| Concentrations | 0.01 mL/g | |
| Incubation Time | 14 d | |
| Results | The mean MVD in the tumors that were treated with vehicle and brivanib was approximately 55.2 ± 9.5 vessels/field and 40.8 ± 17.3 vessels/field, respectively (Fig. 2). |
| Cell Experiment | |
|---|---|
| Cell lines | VEGF or FGF stimulated HUVECs |
| Preparation method | The cells are stimulated by VEGF or FGF at a concentration of 8 or 80 ng/mL. These cells are seeded in 96 well plates at a density of 2 × 103 and incubated for 24 hours. Brivanib at various dilutions are added to the cells for another 48 hours. Then 0.5 μCi of [3H] thymidine is added for 24 hours. After that the incorporated tritium is quantified using a β-counter. |
| Concentrations | ~ 10 μM |
| Incubation time | 48 hours |
| Animal Experiment | |
|---|---|
| Animal models | H3396 xenografts in athymic mice |
| Formulation | Dissolved in PEG400: Tween80 (75:25) (orally) or PEG400: water (3:2) (intravenously) |
| Dosages | 60 mg/kg (orally) or 10 mg/kg (intravenously) |
| Administration | oral or i.v. |
| Molecular Weight | 370.38 |
| Formula | C19H19FN4O3 |
| CAS Number | 649735-46-6 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related VEGFR/PDGFR Products |
|---|
| Conbercept
Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc. |
| SU5208
SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2). |
| VEGFR-IN-1
VEGFR-IN-1 is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively. |
| (Z)-Orantinib
(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively. |
| (Rac)-SAR131675
(Rac)-SAR131675 is the racemate of SAR131675. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
